NASDAQ: AMGNAmgen Inc Stock
AMGN Price
$253.50
Fair Value Price
$268.93
Market Cap
$148.47B
52 Week Low
$177.05
52 Week High
$264.97
P/E
20.3x
P/B
13.55x
P/S
5.95x
PEG
1.31x
Dividend Yield
2.47%
Revenue
$24.99B
Earnings
$7.35B
Gross Margin
76.7%
Operating Margin
37.96%
Profit Margin
29.4%
Debt to Equity
4.9
Operating Cash Flow
$11B
Beta
0.86
Next Earnings
Feb 2, 2021
Ex-Dividend
Feb 11, 2021
Next Dividend
Mar 8, 2021
AMGN Overview
Zen Score
High
Medium
Low
56
Industry average
Reasons for this score
AMGN ($253.50) is undervalued by 5.74% relative to our estimate of its Fair Value price of $268.93 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Valuation
AMGN ($253.50) is trading below its intrinsic value of $833.45, according to Benjamin Graham's Formula from Chapter 14 of "The Intelligent Investor"
Valuation
AMGN is good value based on its earnings relative to its share price (20.3x), compared to the US market average 27.75x)
Valuation
AMGN News
Valuation
AMGN fair value
Fair Value of AMGN stock based on Discounted Cash Flow (DCF)
AMGN ($253.50) is undervalued by 5.74% relative to our estimate of its Fair Value price of $268.93 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Valuation
AMGN ($253.50) is trading below its intrinsic value of $833.45, according to Benjamin Graham's Formula from Chapter 14 of "The Intelligent Investor"
Valuation
AMGN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
20.3x
Industry
-6.05x
Market
27.75x
AMGN is good value based on its earnings relative to its share price (20.3x), compared to the US market average 27.75x)
Valuation
AMGN is good value based on its earnings relative to its share price (20.3x), compared to the US Drug Manufacturers - General industry average (-6.05x)
Valuation
AMGN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
13.55x
Industry
9.7x
Market
61.75x
AMGN is good value based on its book value relative to its share price (13.55x), compared to the US market average (61.75x)
Valuation
AMGN is poor value based on its book value relative to its share price (13.55x), compared to the US Drug Manufacturers - General industry average (9.7x)
Valuation
AMGN price to earnings growth (PEG)
For valuing profitable companies with growth potential
AMGN is poor value relative to its rate of earnings growth, measured by PEG ratio (1.31x)
Valuation
AMGN's financial health
Profit margin
Revenue
$6.4B
Net Income
$2.0B
Profit Margin
31.5%
AMGN's Earnings (EBIT) of $9.48B can safely cover interest payments on company debt ($34.29B)
Financials
AMGN's profit margin has decreased (-5.1%) in the last year from (34.5%) to (29.4%)
Financials
Assets to liabilities
Assets
$64.6B
Liabilities
$53.7B
Debt to equity
3.13
AMGN's short-term assets ($22.66B) exceed its short-term liabilities ($9.95B)
Financials
AMGN's long-term liabilities ($43.73B) exceed its short-term assets ($22.66B)
Financials
AMGN's debt has increased relative to shareholder equity (4.9), over the past 5 years ago (1.57)
Financials
AMGN's debt to equity ratio (4.9) is considered high
Financials
Cash flow
Operating
$3.4B
Investing
-$1.6B
Financing
-$1.8B
AMGN's operating cash flow ($10.86B) is sufficient to service the company's debt ($34.29B)
Financials
Amgen Stock FAQ
©2021 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
